Mohammed Elshiekh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohammed Elshiekh has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alyaa Ahmed Ibrahim
Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 shared publications - Mahmoud Tablawy
Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2 shared publications - Mohamed Fawzi Hemida
Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 shared publications - Abdelrahman Aly Mohamed
Faculty of Medicine, Helwan University, Cairo, Egypt
1 shared publication - Ahmed Sami Fdle
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication - Alaa Eldeeb
Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 shared publication
Latest Publications
- Open Access
- 12 November 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1) , 886
Infant mortality related to congenital heart disease in the United States, 1999–2025: trends, disparities, and projections to 2040
Introduction: Congenital heart disease remains a leading congenital cause of infant mortality in the United States despite major advances in diagnosis and neonatal care. This study evaluated national mortality trends from 1999 to 2025, examined sex and racial disparities, and projected future burden through 2040 using time-series forecasting. Methods: A retrospective CDC WONDER analysis examined U.S. infant (< 1 year) CHD mortality from 1999 to 2025 using ICD-10 codes Q20–Q26. Deaths listing CHD as underlying or contributing cause were included. Crude mortality rates (CMRs) per 100,000 with 95% CIs were calculated. Trends were evaluated using Joinpoint regression analysis to estimate annual percent change (APC) and average annual percent change (AAPC). Forecasts to 2040 used ARIMA and ETS models, stratified by sex and race/ethnicity. Results: From 1999 to 2025, 55,719 infant deaths related to CHD were recorded in the United States, 92.16% in medical facilities. The CMRs declined from 69.66 in 1999 to 46.44 in 2025 (AAPC − 1.32%) and is projected at 37.51 by 2040. Male mortality remained higher than female (54.86 vs. 52.04). NH Black infants had the highest mean mortality (71.87), while NH Asian/Pacific Islander infants showed the steepest decline (AAPC − 2.30%). Recent increases appeared in NH White infants after 2018 (APC 1.56%) and Hispanic infants after 2020 (APC 3.48%) overall. Conclusion: Infant CHD related mortality declined substantially from 1999 to 2025 and is projected to continue decreasing through 2040; however, persistent excess mortality in male, NH Black, and Hispanic infants underscores enduring demographic disparities in outcomes.
- 12 November 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
- Vol. 21 (1) , 886
Open AccessInfant mortality related to congenital heart disease in the United States, 1999–2025: trends, disparities, and projections to 2040
Introduction: Congenital heart disease remains a leading congenital cause of infant mortality in the United States despite major advances in diagnosis and neonatal care. This study evaluated national mortality trends from 1999 to 2025, examined sex and racial disparities, and projected future burden through 2040 using time-series forecasting. Methods: A retrospective CDC WONDER analysis examined U.S. infant (< 1 year) CHD mortality from 1999 to 2025 using ICD-10 codes Q20–Q26. Deaths listing CHD as underlying or contributing cause were included. Crude mortality rates (CMRs) per 100,000 with 95% CIs were calculated. Trends were evaluated using Joinpoint regression analysis to estimate annual percent change (APC) and average annual percent change (AAPC). Forecasts to 2040 used ARIMA and ETS models, stratified by sex and race/ethnicity. Results: From 1999 to 2025, 55,719 infant deaths related to CHD were recorded in the United States, 92.16% in medical facilities. The CMRs declined from 69.66 in 1999 to 46.44 in 2025 (AAPC − 1.32%) and is projected at 37.51 by 2040. Male mortality remained higher than female (54.86 vs. 52.04). NH Black infants had the highest mean mortality (71.87), while NH Asian/Pacific Islander infants showed the steepest decline (AAPC − 2.30%). Recent increases appeared in NH White infants after 2018 (APC 1.56%) and Hispanic infants after 2020 (APC 3.48%) overall. Conclusion: Infant CHD related mortality declined substantially from 1999 to 2025 and is projected to continue decreasing through 2040; however, persistent excess mortality in male, NH Black, and Hispanic infants underscores enduring demographic disparities in outcomes.
- Open Access
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48559
Examining the link between tobacco use and gastric cancer mortality: A US population-based perspective (2003 to 2023)
Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, driven by multiple risk factors including infection, diet, genetics, and lifestyle behaviors. Tobacco use is a well-established modifiable risk factor that contributes to gastric carcinogenesis through chronic mucosal injury. This study aimed to evaluate long-term mortality trends of tobacco-associated GC among United States adults aged ≥ 25 years. We conducted a retrospective cross-sectional analysis using the CDC WONDER Multiple Cause of Death database from 2003 to 2023. Adults aged ≥ 25 years with GC (International Classification of Diseases, Tenth Revision: C16) and tobacco use disorder (International Classification of Diseases, Tenth Revision: F17) listed as underlying or contributing causes of death were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal trends were assessed using Joinpoint regression, reporting annual percent change and average annual percent change (AAPC). A total of 17,357 deaths were attributed to tobacco-associated GC (overall AAMR: 0.34). Mortality was higher among males (AAMR: 0.58) compared with females (AAMR: 0.15), with comparable temporal trends (AAPC: 4.59% vs 4.58%, respectively). Overall AAMR increased significantly from 0.15 in 2003 to 0.40 in 2023 (AAPC: 4.60%; 95% confidence interval: 3.11–6.18). Across racial groups, non-Hispanic (NH) Black individuals exhibited the highest mortality burden (AAMR: 0.56). However, NH White individuals demonstrated the steepest relative increase over time (AAPC: 3.89%). Regionally, the Midwest had the highest mortality burden (AAMR: 0.45) and the fastest growth (AAPC: 7.33%). Nonmetropolitan areas showed higher mortality (AAMR: 0.45) and a greater increase (AAPC: 4.73%) than metropolitan areas (AAMR: 0.33; AAPC: 4.14%). Tobacco-associated GC mortality has increased significantly in the United States from 2003 to 2023. While NH Black individuals bear the greatest overall mortality burden, NH White individuals exhibit the steepest rise in mortality rates. Higher burden and growth in the Midwest and rural areas highlight persistent geographic disparities.
- 8 May 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (19) , e48559
Open AccessExamining the link between tobacco use and gastric cancer mortality: A US population-based perspective (2003 to 2023)
Gastric cancer (GC) remains a major cause of cancer-related mortality worldwide, driven by multiple risk factors including infection, diet, genetics, and lifestyle behaviors. Tobacco use is a well-established modifiable risk factor that contributes to gastric carcinogenesis through chronic mucosal injury. This study aimed to evaluate long-term mortality trends of tobacco-associated GC among United States adults aged ≥ 25 years. We conducted a retrospective cross-sectional analysis using the CDC WONDER Multiple Cause of Death database from 2003 to 2023. Adults aged ≥ 25 years with GC (International Classification of Diseases, Tenth Revision: C16) and tobacco use disorder (International Classification of Diseases, Tenth Revision: F17) listed as underlying or contributing causes of death were included. Age-adjusted mortality rates (AAMRs) per 100,000 population were calculated. Temporal trends were assessed using Joinpoint regression, reporting annual percent change and average annual percent change (AAPC). A total of 17,357 deaths were attributed to tobacco-associated GC (overall AAMR: 0.34). Mortality was higher among males (AAMR: 0.58) compared with females (AAMR: 0.15), with comparable temporal trends (AAPC: 4.59% vs 4.58%, respectively). Overall AAMR increased significantly from 0.15 in 2003 to 0.40 in 2023 (AAPC: 4.60%; 95% confidence interval: 3.11–6.18). Across racial groups, non-Hispanic (NH) Black individuals exhibited the highest mortality burden (AAMR: 0.56). However, NH White individuals demonstrated the steepest relative increase over time (AAPC: 3.89%). Regionally, the Midwest had the highest mortality burden (AAMR: 0.45) and the fastest growth (AAPC: 7.33%). Nonmetropolitan areas showed higher mortality (AAMR: 0.45) and a greater increase (AAPC: 4.73%) than metropolitan areas (AAMR: 0.33; AAPC: 4.14%). Tobacco-associated GC mortality has increased significantly in the United States from 2003 to 2023. While NH Black individuals bear the greatest overall mortality burden, NH White individuals exhibit the steepest rise in mortality rates. Higher burden and growth in the Midwest and rural areas highlight persistent geographic disparities.